Current Report Filing (8-k)
28 December 2017 - 10:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December
14, 2017
AMPIO
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in Charter)
|
Delaware
|
|
001-35182
|
|
26-0179592
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification No.)
|
373 Inverness Parkway, Suite 200
Englewood, Colorado 80112
(Address of principal executive offices,
including zip code)
(720) 437-6500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging
growth company
¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
¨
On December 14, 2017, Ampio Pharmaceuticals, Inc. (“Ampio”)
issued a press release announcing the results of its Phase 3 clinical trial of Ampion for sever osteoarthritis of the knee. The
Phase 3 clinical trial met its primary endpoint with 71% of Ampion treated patients meeting the OMERACT-OARSI responder criteria.
Ampio plans to present a more detailed analysis of the Phase 3 and pooled data at an upcoming scientific meeting as well as submission
for publication. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AMPIO PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Thomas E. Chilcott, III
|
|
|
Thomas E. Chilcott, III
|
|
|
Chief Financial Officer
|
Dated: December 28, 2017
EXHIBIT INDEX
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ampio Pharmaceuticals (AMEX:AMPE)
Historical Stock Chart
From Jul 2023 to Jul 2024